Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies.

CONCLUSION: Overall, SST and CXCR4 expression levels are clearly of no therapeutic relevance in PCa. SST- or CXCR4-based therapy might be feasible, however, in rare cases of small-cell-type neuroendocrine carcinoma of the prostate. PMID: 32460182 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32460182?dopt=Abstract

Source: Translational Oncology - May 23, 2020 Category: Cancer & Oncology Authors: Werner C, Dirsch O, Dahmen U, Grimm MO, Schulz S, Lupp A Tags: Transl Oncol Source Type: research